Healthy Returns: Wall Street mulls over Amgen’s weight loss drug data

A version of this article at the start appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to walk off future editions.

Wall Street is chewing over critical data released last week on Amgen’s exploratory weight loss injection – a potential competitor in the blockbuster obesity drug market. 

Some analysts said the opening mid-stage trial results appear positive overall. But questions remain about the drug’s efficacy and how well patients stick it, they noted. 

We likely won’t get more answers until the company releases the full data from the study. That encompasses results from a second part of the trial, which examines how long MariTide’s weight loss lasts. 

Investors initially weren’t walking on air. Shares of Amgen tumbled more than 11% as the markets opened last Tuesday, as the results appeared to be shed weight below Wall Street’s lofty expectations for the drug.

The injection, MariTide, helped patients with obesity use up up to 20% of their weight on average after a year, with no plateau. Ahead of the data, several analysts imparted they wanted MariTide to show weight loss of at least 20% in the phase two trial, with some longing for up to 25%. 

Here’s how that compares to the existing injections on the market, based on late-stage studies:

• Novo Nordisk‘s Wegovy showed that it led to 15% authority loss over 68 weeks 
• Eli Lilly‘s Zepbound helped patients lose more than 22% of their bias over 72 weeks

But in a note last week, BMO Capital Markets analyst Evan Seigerman said the variety reaction last Tuesday reflects “too-high expectations for % weight loss, without assigning value to easier dosage” of the injection. 

Notably, Amgen is testing MariTide as an injection taken once a month or even less frequently, which would be far profuse convenient for patients to take long term than the weekly injections from Novo Nordisk and Eli Lilly. 

“MariTide details firmly establishes Amgen as a competitor in obesity and diabetes indications, today showing compelling weight loss in both clues,” Seigerman said. 

In the trial, MariTide also helped patients with obesity and Type 2 diabetes lose up to 17% of their force after a year.

The drug’s efficacy may also improve, Jefferies analyst Michael Yee said in a note last week. The 20% load loss after one year, with no plateau, may increase to 25% by 18 months, Yee said. He noted that in resemblance, the weight loss caused by Zepbound mostly plateaued by a year. 

The most common side effects for MariTide were gastrointestinal, including nausea, vomiting and constipation. Nausea and heaving were mainly mild and associated with the first dose of MariTide. 

Amgen said incidences of nausea and vomiting were also significantly curtailed with dose escalation, which refers to starting patients at a lower dose of MariTide and gradually increasing it upward of a specific time period until they reach a higher target dose. 

Roughly 11% of patients in conglomerations with dose escalation discontinued treatment because of any adverse side effects, while less than 8% ended specifically due to gastrointestinal side effects such as nausea and vomiting. 

Amgen reported that 70% of patients in guilds with dose escalation experienced nausea and 40% experienced vomiting. 

However, Amgen said it conducted another early-stage read that found starting patients with lower initial doses of MariTide cut those rates substantially, cardinal to about 50% of patients reporting nausea and 20% reporting vomiting. 

That appears to be higher than the bulldozes of nausea and vomiting seen for Zepbound and Wegovy. Still, Seigerman said the mild severity of those side imports and “isolated time of events at the start of treatment give us confidence they can be managed.” 

He added that he is “encouraged by the reductions espied with dose escalations.” 

In a research note last week, JPMorgan analyst Chris Schott said Amgen bequeath explore lower starting doses in its phase three trial on MariTide. The firm believes that “further set righted tolerability in the Ph3 trial will be key to potential uptake for the asset,” he noted. 

Leerink Partners analyst David Risinger, in a note ultimate week, outlined key questions that need clarification when full results from the trial are released. He explained that includes detailed data on how well patients tolerated the drug when dose escalation wasn’t hand-me-down, and weight loss data among non-diabetic patients that received the highest dose of the drug. 

Feel unconditioned to send any tips, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.

GE HealthCare on Monday announced it will fully acquire the Japanese radiopharmaceutical company Nihon Medi-Physics (NMP). GE HealthCare has deemed a 50% stake in the company since 2004, and it will purchase the remaining half from Sumitomo Chemical, go together to a release.

The Tokyo-based NMP was founded in 1973. The company manufactures radiopharmaceuticals, a special type of radioactive drug that can be second-hand to treat some cancers and carry out imaging tests. NMP runs 13 manufacturing facilities, and the company conducts its own correlated research and development, GE HealthCare said.

Radiopharmaceuticals are becoming an increasingly competitive market, as companies like Bristol Myers Squibb, AstraZeneca, Eli Lilly and Novartis rallye to develop them. Two radiopharmaceuticals from Novartis, Pluvicto and Lutathera, are already available in the U.S.

NMP generated around $183 million in profits last year, according to the release. Prior to Monday’s announcement, GE HealthCare held three seats on NMP’s board of guides.  

“This will strengthen our precision care strategy in Asia and our existing footprint in Japan, where our contrast milieu and medical devices are used every day to enable imaging procedures across the country,” Kevin O’Neill, president & CEO of the Pharmaceutical Diagnostics fragment of GE HealthCare, said in the release.

The terms of the deal were not disclosed, and it is expected to close early next year, according to the releasing. The acquisition is still subject to regulatory approval. 

Solomon Partners advised GE HealthCare on the transaction. 

GE HealthCare announced the possessions during the Radiological Society of North America’s 2024 annual meeting in Chicago, where it has shared a number of additional updates. This week, the companions has unveiled a new 3D MRI research foundation model, a new ​​SPECT/CT solution and a new submission to the U.S. Food and Drug Administration, among other things.

Peruse the full release about GE HealthCare’s acquisition of NMP here.

Feel free to send any tips, suggestions, story convictions and data to Ashley at ashley.capoot@nbcuni.com.